Should you buy Digico, Magellan, and Ramelius shares?

Morgans has given its verdict on these shares. Are they buys? Let's find out.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a lot of ASX shares to choose from on the Australian share market.

To narrow things down, let's take a look at three that analysts at Morgans have just given their verdict on.

Is it bullish or bearish? Here's what the broker is saying:

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, and holding a mobile phone in his other hand.

Image source: Getty Images

DigiCo Infrastructure REIT (ASX: DGT)

This data centre investment company's shares could be dirt cheap according to Morgans. It notes that its shares are trading at a 50% discount to its net asset value (NAV).

It also highlights that this NAV estimate does not include the 88MW SYD1 expansion, which could add a further $1.50 per share to its NAV. In light of this, the broker has put a buy rating and $4.15 price target on its shares. It said:

DGT continues to trade at a c.50% discount to NAV of A$4.62/security, yet that NAV does not yet reflect the full value of the 88MW SYD1 expansion, which management estimates will deliver a further c.A$1.50/security of NAV uplift at a targeted 15% yield on cost. The core thesis rests on three pillars. First, SYD1 is a genuinely scarce asset, a Tier 1 CBD carrier hotel with secured power and full planning approval operating in a structurally undersupplied market with a 200MW+ qualified demand pipeline.

Second, the business has demonstrated operating momentum, yet cash earnings are yet to materialise. Third, Australian capital partnering at or above book value would be a significant valuation catalyst. Acknowledging the share price weakness, we continue to see the opportunity in DGT, retaining our Buy rating with a $4.15/sh price target.

Magellan Financial Group Ltd (ASX: MFG)

Morgans isn't as positive on this fund manager's shares. In response to its half-year results, the broker has put a hold rating and $9.80 price target on its shares.

The broker feels that its shares are fully valued, especially given that the core business remains challenged. It said:

MFG's 1H26 operating profit after tax (A$83m) was flat on the pcp, but appeared comfortably above (+20%) Factset consensus (A$68m). Overall, whilst this result showed MFG's investment in Barrenjoey is shaping as a winner (with upside), there is still significant work to do turning around MFG's core Investment management franchise.

Following a change of analyst, we update our numbers and price target with this note. Our PT is set at $9.80 (previously (A$10.74) and stock coverage is transferred to Richard Coles. We maintain a HOLD rating on MFG, with the stock trading at only a 5% discount to our Blended valuation. Growth in the core business is still challenged (with downside risk), however we acknowledge optionality from current and future strategic investments.

Ramelius Resources Ltd (ASX: RMS)

This gold miner delivered a half-year result in line with expectations last week according to Morgans.

And while there were positives and negatives from the half, the broker remains positive and has retained its buy rating with a $5.75 price target. It said:

1H26 result was solid with no material surprises, FY26 continues to focus on the integration of Dalgaranga (acquired via ASX SPR) into the RMS asset portfolio. Key positive: Introduction of new capital management framework and the spartan deal; A$84.9m (net) tax losses remain. Key negative: Operating cash flow (-3% pcp), free cash flow (-15% pcp) and cash/bullion on hand (-14% pcp) reflect the anticipated grade decline across the RMS Magnet Hub assets.

This was well flagged and should begin to reverse as Dalgaranga ore is introduced into the Magnet operations and ramps through the system, marking the transition to the next phase of higher-grade feed – we forecast Dalgaranga alone to contribute +A$700m per annum from FY28 onwards. We maintain our BUY rating, price target A$5.75ps (previously A$5.76).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Morgans names 2 ASX shares to buy and 1 to accumulate

What is the broker recommending investors do with these shares?

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

2 ASX 200 shares to buy ahead of anticipated rally: expert

After a 9.1% drop between 27 February and 23 March, the ASX 200 reversed course last Tuesday.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Broker Notes

Bell Potter says this ASX 200 stock can rise 38% and pay a 6% dividend yield

Major upside and a generous dividend yield could be on offer with this name.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

Is this ASX defence stock the next DroneShield?

Bell Potter thinks this stock could be the next to rocket. Let's find out why.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Broker Notes

This ASX healthcare stock could almost double in value according to Bell Potter

The broker believes this stock is making major breakthroughs.

Read more »

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

a miner holds his thumb up as he holds a device in his other hand.
Resources Shares

Experts name 3 ASX mining shares to buy after March sell-off

Investors took profits amid fears the fuel crisis could impact miners' production and earnings.

Read more »